A blockbuster heart drug just failed a massive trial. The reflexive takeaway — “inflammation doesn’t matter” — is exactly ...

Intel priced a $20B stock raise, boosting dilution as capex outpaces foundry revenue and customer wins remain unproven.

As Japan turns back mangoes, China blocks rice, and European inspectors flag spices, India's growers ask what's wrong.